Genmab A/S- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Genmab A/S 公司

Genmab A/S 是一家总部位于丹麦的国际生物技术公司。该公司专门从事用于治疗癌症的抗体疗法的研发。该公司是以下获批抗体的创造者：用于治疗某些多发性骨髓瘤适应症的 DARZALEX（daratumumab）、用于治疗复发型多发性硬化症成人患者的 Kesimpta、用于治疗甲状腺眼病的 TEPEZZA（teprotumumab）和用于治疗某些多发性骨髓瘤适应症成人患者的 FASPRO。Genmab 创造的首个获批疗法 Arzerra 获批用于治疗某些慢性淋巴细胞白血病适应症，在日本有售，也可通过同情用药或肿瘤学获取计划在其他地区有售。Genmab 开发了广泛的临床和临床前产品线，拥有四种抗体技术，即 DuoBody 双特异性平台、HexaBody 平台、DuoHexaBody 平台和 HexElect 平台。

Genmab A/S简介



公司代码GMAB

公司名称Genmab A/S

上市日期Oct 01, 2000

CEODr. Jan G.J. Van De Winkel, Ph.D.

员工数量2682

证券类型Ordinary Share

年结日Oct 01

公司地址Carl Jacobsens Vej 30

城市VALBY

上市交易所OMX Nordic Exchange Copenhagen A/S

国家Denmark

邮编2500

电话4570202728

网址https://www.genmab.com/

公司代码GMAB

上市日期Oct 01, 2000

CEODr. Jan G.J. Van De Winkel, Ph.D.

Genmab A/S公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.

Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

--

Dr. Judith V. Klimovsky, M.D.

Executive Vice President, Chief Development Officer

--

Ms. Pernille Lyngvold Erenbjerg

Independent Deputy Chairman of the Board

--

Mr. Christopher Cozic

Executive Vice President, Chief People Officer

--

Mr. Martin Schultz

Non-Independent Director, Employee Elected

--

Dr. Anders Gersel Pedersen, M.D., Ph.D.

Non-Independent Director

--

Dr. Paolo Paoletti, M.D.

Independent Director

--

Dr. Jan G.J. Van De Winkel, Ph.D.

President, Chief Executive Officer

--

Ms. Mijke Zachariasse, Ph.D.

Non-Independent Director, Employee Elected

--

Ms. Elizabeth A. O'farrell

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.

Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

--

Dr. Judith V. Klimovsky, M.D.

Executive Vice President, Chief Development Officer

--

Ms. Pernille Lyngvold Erenbjerg

Independent Deputy Chairman of the Board

--

Mr. Christopher Cozic

Executive Vice President, Chief People Officer

--

Mr. Martin Schultz

Non-Independent Director, Employee Elected

--

Dr. Anders Gersel Pedersen, M.D., Ph.D.

Non-Independent Director

--

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Royalties

789.00M

85.30%

Net product sales

101.00M

10.92%

Collaboration revenue

21.00M

2.27%

Reimbursement income

13.00M

1.41%

Milestone payments

1.00M

0.11%

暂无数据

业务

地区

业务USD

名称

营收

占比

Royalties

789.00M

85.30%

Net product sales

101.00M

10.92%

Collaboration revenue

21.00M

2.27%

Reimbursement income

13.00M

1.41%

Milestone payments

1.00M

0.11%

股东统计

更新时间: 11月8日周六

持股股东

股东类型

持股股东

占比

AllianceBernstein L.P.

1.73%

Orbis Investment Management Ltd.

1.29%

Citadel Advisors LLC

0.58%

Arrowstreet Capital, Limited Partnership

0.56%

Two Sigma Investments, LP

0.56%

其他

95.28%

持股股东

占比

AllianceBernstein L.P.

1.73%

Orbis Investment Management Ltd.

1.29%

Citadel Advisors LLC

0.58%

Arrowstreet Capital, Limited Partnership

0.56%

Two Sigma Investments, LP

0.56%

其他

95.28%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

4.32%

Investment Advisor

3.18%

Hedge Fund

2.35%

Research Firm

0.64%

Pension Fund

0.03%

Bank and Trust

0.02%

Family Office

0.01%

其他

89.45%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

515

64.81M

10.54%

-15.68M

2025Q2

501

65.30M

10.31%

-6.21M

2025Q1

515

65.99M

10.42%

-5.32M

2024Q4

512

61.76M

9.33%

+621.44K

2024Q3

493

53.46M

8.41%

-4.14M

2024Q2

495

49.90M

7.86%

-6.30M

2024Q1

501

49.04M

7.53%

-7.16M

2023Q4

490

47.86M

7.32%

-6.37M

2023Q3

479

48.54M

7.43%

+204.98K

2023Q2

467

42.76M

6.55%

-5.77M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

AllianceBernstein L.P.

10.66M

1.73%

-4.06M

-27.59%

Jun 30, 2025

Orbis Investment Management Ltd.

7.92M

1.29%

+2.21M

+38.69%

Jun 30, 2025

Citadel Advisors LLC

3.57M

0.58%

-857.47K

-19.37%

Jun 30, 2025

Arrowstreet Capital, Limited Partnership

3.45M

0.56%

+2.08M

+152.25%

Jun 30, 2025

Two Sigma Investments, LP

3.44M

0.56%

-433.92K

-11.20%

Jun 30, 2025

Harding Loevner LP

2.92M

0.48%

+42.61K

+1.48%

Jun 30, 2025

Renaissance Technologies LLC

2.77M

0.45%

+504.40K

+22.30%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.50M

0.41%

-443.29K

-15.04%

Jun 30, 2025

Marshall Wace LLP

1.91M

0.31%

-274.23K

-12.57%

Jun 30, 2025

First Trust Advisors L.P.

1.77M

0.29%

+60.50K

+3.54%

Jun 30, 2025

持股ETF



更新时间: 11月6日周四

机构名称

占比

Tema Oncology ETF

5.08%

First Trust NYSE Arca Biotechnology Index Fund

4.45%

WisdomTree BioRevolution Fund

1.33%

iShares Biotechnology ETF

1.32%

AB Disruptors ETF

0.92%

First Trust NASDAQ BuyWrite Income ETF

0.29%

ProShares Ultra Nasdaq Biotechnology

0.13%

Invesco Nasdaq Biotechnology ETF

0.13%

ActivePassive International Equity ETF

0.13%

Avantis International Equity ETF

0.1%

Tema Oncology ETF

占比5.08%

First Trust NYSE Arca Biotechnology Index Fund

占比4.45%

WisdomTree BioRevolution Fund

占比1.33%

iShares Biotechnology ETF

占比1.32%

AB Disruptors ETF

占比0.92%

First Trust NASDAQ BuyWrite Income ETF

占比0.29%

ProShares Ultra Nasdaq Biotechnology

占比0.13%

Invesco Nasdaq Biotechnology ETF

占比0.13%

ActivePassive International Equity ETF

占比0.13%

Avantis International Equity ETF

占比0.1%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据